These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 36227953)

  • 21. Invasive meningococcal disease epidemiology and control measures: a framework for evaluation.
    Caro JJ; Möller J; Getsios D; Coudeville L; El-Hadi W; Chevat C; Nguyen VH; Caro I
    BMC Public Health; 2007 Jun; 7():130. PubMed ID: 17603880
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Vaccination and herd immunity: what more do we know?
    Rashid H; Khandaker G; Booy R
    Curr Opin Infect Dis; 2012 Jun; 25(3):243-9. PubMed ID: 22561998
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Interplay between cost and benefits triggers nontrivial vaccination uptake.
    Steinegger B; Cardillo A; Rios PL; Gómez-Gardeñes J; Arenas A
    Phys Rev E; 2018 Mar; 97(3-1):032308. PubMed ID: 29776104
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Global optimal vaccination in the SIR model: properties of the value function and application to cost-effectiveness analysis.
    Laguzet L; Turinici G
    Math Biosci; 2015 May; 263():180-97. PubMed ID: 25771436
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Information sharing and coordination in a vaccine supply chain.
    Pan Y; Ng CT; Dong C; Cheng TCE
    Ann Oper Res; 2022 Feb; ():1-24. PubMed ID: 35194284
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A simulation analysis to characterize the dynamics of vaccinating behaviour on contact networks.
    Perisic A; Bauch CT
    BMC Infect Dis; 2009 May; 9():77. PubMed ID: 19476616
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dynamical vaccination behavior with risk perception and vaccination rewards.
    Wang X; Li J; Liu J; Wu X
    Chaos; 2024 Mar; 34(3):. PubMed ID: 38442233
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-effectiveness of conjugate pneumococcal vaccination in Singapore: comparing estimates for 7-valent, 10-valent, and 13-valent vaccines.
    Tyo KR; Rosen MM; Zeng W; Yap M; Pwee KH; Ang LW; Shepard DS
    Vaccine; 2011 Sep; 29(38):6686-94. PubMed ID: 21745516
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Herd immunity and epidemic size in networks with vaccination homophily.
    Hiraoka T; Rizi AK; Kivelä M; Saramäki J
    Phys Rev E; 2022 May; 105(5):L052301. PubMed ID: 35706197
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacoeconomic and epidemiological bases of optimal rotavirus vaccine supply for Ukrainian population.
    Soloviov SO; Mokhort HA; Trokhimenko OP; Zahoriy HV; Trokhymchuk VV; Kolesnikova IP; Dziublyk IV
    Wiad Lek; 2019; 72(7):1274-1280. PubMed ID: 31398155
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-effectiveness of heptavalent conjugate pneumococcal vaccine (Prevenar) in Germany: considering a high-risk population and herd immunity effects.
    Lloyd A; Patel N; Scott DA; Runge C; Claes C; Rose M
    Eur J Health Econ; 2008 Feb; 9(1):7-15. PubMed ID: 17333089
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Imperfect vaccine aggravates the long-standing dilemma of voluntary vaccination.
    Wu B; Fu F; Wang L
    PLoS One; 2011; 6(6):e20577. PubMed ID: 21687680
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-effectiveness analysis of pneumococcal conjugate vaccination in England and Wales.
    Melegaro A; Edmunds WJ
    Vaccine; 2004 Oct; 22(31-32):4203-14. PubMed ID: 15474710
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Analyzing the Costs and Benefits of Utilizing a Mixed-Strategy Approach in Infectious Disease Control under a Voluntary Vaccination Policy.
    Kabir KMA; Ullah MS; Tanimoto J
    Vaccines (Basel); 2023 Sep; 11(9):. PubMed ID: 37766152
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of population heterogeneity on herd immunity and on vaccination decision making process.
    Bai F
    J Theor Biol; 2021 Oct; 526():110795. PubMed ID: 34102199
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost effectiveness of adding 7-valent pneumococcal conjugate (PCV-7) vaccine to the Norwegian childhood vaccination program.
    Wisløff T; Abrahamsen TG; Bergsaker MA; Løvoll Ø; Møller P; Pedersen MK; Kristiansen IS
    Vaccine; 2006 Jul; 24(29-30):5690-9. PubMed ID: 16735083
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Addressing vaccine hesitancy requires an ethically consistent health strategy.
    Williamson L; Glaab H
    BMC Med Ethics; 2018 Oct; 19(1):84. PubMed ID: 30355355
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Behavioral vaccination policies and game-environment feedback in epidemic dynamics.
    Ariful Kabir KM
    Sci Rep; 2023 Sep; 13(1):14520. PubMed ID: 37666863
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Analysis of epidemic vaccination strategies on heterogeneous networks: Based on SEIRV model and evolutionary game.
    Meng X; Cai Z; Si S; Duan D
    Appl Math Comput; 2021 Aug; 403():126172. PubMed ID: 33758440
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Vaccination, herd behavior, and herd immunity.
    Cohen MJ; Brezis M; Block C; Diederich A; Chinitz D
    Med Decis Making; 2013 Nov; 33(8):1026-38. PubMed ID: 23695369
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.